news
Patients must get the medicine they need after Brexit
Patients could find that supplies of their medicines will be disrupted when the UK leaves the EU, according to a new briefing published by the Brexit Health Alliance...
List view / Grid view
ABPI (Association of the British Pharmaceutical Industry)
news
Clinical trial transparency reaches record level
Disclosure rate of industry-sponsored clinical trials at 12 months has significantly improved year on year from 71% in 2009 to 93% in 2014, according to ABPI-sponsored study.
news
Joint policy document shows the potential impact of Brexit
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union...
news
Budget 2017: Reaction from the UK’s pharmaceutical industry
The Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), Mike Thompson responds to the UK’s Budget announcement...
news
Bluebird bio joins the ABPI as a full member
The Association of the British Pharmaceutical Industry (ABPI) has admitted the American biotech bluebird bio, Inc. as a full member...
article
SynBio: unlocking the commercial potential of a new bioscience industry
An exclusive column from the ABPI's Magda Papadaki about the implications of synthetic biology for the pharmaceutical industry...
news
UK trails behind EU in cancer diagnosis & treatment
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
news
ABPI respond to statement of UK Government’s medicines regulation plans
The ABPI has responded to a joint letter from Jeremy Hunt, Secretary of State for Health, and Greg Clark, Secretary of State for Business, published by the Financial Times, that outlined the UK Government’s plans for the regulation of medicines as the UK leaves the European Union (EU).
news
Collaboration is ‘game changer’ in delivering cell and gene therapies
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
news
Saratha Rajeswaran joins ABPI as Executive Director
2 June 2017 | By Niamh Marriott, Junior Editor
Sara Rajeswaran has joined the Association of the British Pharmaceutical Industry as the new Executive Director of Government Affairs and Devolved Nations.
news
UK life sciences sector productivity double national average
7 March 2017 | By Steve Bremer, Managing Editor
The PwC report, commissioned by the Association of the British Pharmaceutical Industry (ABPI) and supported by the Association of the British Healthcare Industry (ABHI), the BioIndustry Association (BIA), and the British In Vitro Diagnostics Association (BIVDA), shows that the average productivity of UK life sciences employees, expressed as gross value…
news
Pharmaceutical industry to pay £550 million in 2016 as part of the PPRS
22 December 2015 | By Victoria White
The PPRS is a unique scheme where pharmaceutical companies agreed to contribute towards the cost of medicines, with the aim of making the latest treatments affordable for the NHS...
news
ABPI and OBN announce Memorandum of Understanding
13 October 2014 | By ABPI and OBN
The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK’s emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding...
news
Sanofi to expand access to Clinical Trial Data
2 January 2014 | By Sanofi
“Sanofi has a history of contributing in this collective effort of sharing clinical trial data and results with researchers and patients with initiatives such as Project Data Sphere..."
news
New carbon footprint tool launched to calculate the carbon footprint of pharmaceutical products
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
